Original Post on medium.com Don’t mistake “wants” for “needs” in your life. We hardly need anything to survive, and if we don’t get caught up on the materialistic world that media, corporations, and politicians sell us in order to perpetuate their agendas, it leaves us free to pursue our passions. Passion is the “secret sauce”…

Original Post on lifescivoice.com and written by: Jeff Galvin It’s a tragic irony: So much money has been poured into treating diseases, but far less into actually curing them. The pharmaceutical industry has done an incredible job of developing highly profitable treatments for a wide range of diseases and conditions. Those treatments have generated trillions…

Original Post on DNAWeekly and written by: Ditsa Keren American Gene Technologies (AGT) is a cutting-edge biotechnology company creating technologies that speed up the development of cures and treatments in the emerging field of gene therapy. In this interview, founder and CEO Jeff Galvin pinpoints the current challenges in drug development and offers a unique perspective on the…

[This webpage is not searchable via search engines out of respect for the original publisher who owns the content. This copy is only rendered here for AGT readers]. Published on: WUSA9 | BY Lorenzo Hall Published: 5:18 PM EDT July 5, 2021 American Gene Technologies is celebrating a milestone in its HIV Cure Program, which is currently…

Subscribe to our YouTube Channel Jeff Galvin, CEO of American Gene Technologies, presents AGT’s latest news at the BIO Digital International Convention 2021. As the first patient in AGT’s Phase 1 clinical trial is infused with AGT103-T, an autologous cell therapy intended to cure HIV, the company expects to see safety data by the end…

Published on: Bethesda Magazine | BY DAVID GOLDSTEIN Jeff Galvin believes his Rockville cell and gene technology company has found a breakthrough treatment for people living with HIV When Jeff Galvin was 13 years old, he came across a lone computer in the basement of Muzzey Junior High School in Lexington, Massachusetts. It was actually a…

Original Article: Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020 Haishan Li,1 Tyler Lahusen,1 Lingzhi Xiao,1 Nidal Muvarak,1 Jana Blazkova,2 Tae-Wook Chun,2 and C. David Pauza1 1American Gene Technologies International, Rockville, MD, USA; 2Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA Activation, infection, and eventual depletion of…

The rapid growth of biopharma is causing a shift to a new paradigm for the drug development and delivery model. In the same manner that the personal computing industry grew and developed business models that fit the way products were sourced, constructed and delivered, a business model for biopharma is taking shape. Jeff Galvin, CEO…

Published by:  Zacks Small Cap Research (SCR)  |  Written by:  John Vandermosten, CFA Download The Full PDF American Gene Technologies (AGT) is a genetic medicines company developing a portfolio of therapies that employ the company’s proprietary lentiviral vector (LV) platform to focus on disease in areas of unmet medical need. AGT’s pipeline consists of therapies…

Published by: Parenteral Drug Association (PDA), In: Volume LV, Issue 9  |  Written by: Rebecca Stauffer Download The Full PDF What if developers of cell and gene therapies treated their products like software releases? What if the human body could be manipulated like a highly complex computer? Jeff Galvin, CEO of American Gene Technologies, certainly has that…

Published by: abc4.com  Written by: Janay Parrott ROCKVILLE, Md. (WDVM) – Wednesday night was an exciting one for investors and employees at American Gene Technologies. After years in the making, they submitted a nearly 1,000-page document to FDA. And within its pages just may lie the cure for HIV/AIDS. American Gene Technologies (AGT) announced the…

Published by: BiotechPrimer  Written by: Emily Burke, PhD For many years, a diagnosis of acquired immunodeficiency syndrome (AIDS) was a death sentence. It seemed unthinkable in the 1980s, but the medical community now largely treats the disease as a chronic illness. This profound shift arose through the development of highly active antiretroviral therapies (HAART). These medicines…